Cell division cycle 25C (CDC25C) expression confers poor prognosis in invasive breast cancer

Ojiegbe, S.; Joseph, C.; Provenzano, E.; Caldas, C.; Nolan, C.; Green, A.R.; Rakha, E.; Ellis, I.O.; Mukherjee, A.

Abstract

Background: CDC25C, belonging to the Cdc25 phosphatase family, plays a major role in cell cycle control, impacting on DNA repair and apoptosis. It has been shown that poor prognosis/copy number high Luminal A breast cancers (BCs) are enriched for the Aurora kinase pathway including CDC25C leading to CDK1 activation (Ciriello et al, Breast Cancer Research Treatment, 2013:409). This study examined the associations of CDC25C with clinicopathological and molecular features in BCs including the low grade ER positive cohort.
Methodology: CDC25C mRNA expression was studied in the METABRIC BC cohort (n=1980) and externally validated using online expression datasets [bc-GenExMiner v4.0]. CDC25C protein expression level was assessed immunohistochemically on a large annotated series of BC (n= 1330) and correlations made with clinicopathological parameters and patient outcome.
Results: High CDC25C expression was significantly associated with poor prognostic factors including high grade, large tumour size, medullary like tumours, poorer NPI, ER-/PR- Her2+ status (p

Citation

Ojiegbe, S., Joseph, C., Provenzano, E., Caldas, C., Nolan, C., Green, A., …Mukherjee, A. (2017). Cell division cycle 25C (CDC25C) expression confers poor prognosis in invasive breast cancer.

• Conference Name: Belfast Pathology 2017: 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland
• End Date: Jun 23, 2017
• Acceptance Date: Apr 7, 2017
• Publication Date: Jun 20, 2017
• Deposit Date: Jul 7, 2017
• Publicly Available Date: Jul 7, 2017
• Peer Reviewed: Peer Reviewed
• Public URL: https://nottingham-repository.worktribe.com/output/867359
• Publisher URL: https://www.path.org.uk/wp-content/uploads/2017/06/BP2017-PLENARY-ORAL-ABSTRACTS-05.06.17.pdf